ORPHAGEN PHARMACEUTICALS AWARDED SBIR PHASE II GRANT TO DEVELOP A FIRST-IN-CLASS DRUG FOR ADRENOCORTICAL CANCER - Orphagen Pharmaceuticals
Orphagen Pharmaceuticals received a $2.0 million SBIR grant from the NCI for preclinical development of OR-449, a first-in-class therapy targeting adrenocortical carcinoma (ACC). OR-449 inhibits SF-1, crucial for ACC pathogenesis. Orphagen's CEO highlighted the team's expertise in discovering OR-449, aiming to advance ACC treatment.
Reference News
ORPHAGEN PHARMACEUTICALS AWARDED SBIR PHASE II GRANT TO DEVELOP A FIRST-IN-CLASS DRUG FOR ADRENOCORTICAL CANCER - Orphagen Pharmaceuticals
Orphagen Pharmaceuticals received a $2.0 million SBIR grant from the NCI for preclinical development of OR-449, a first-in-class therapy targeting adrenocortical carcinoma (ACC). OR-449 inhibits SF-1, crucial for ACC pathogenesis. Orphagen's CEO highlighted the team's expertise in discovering OR-449, aiming to advance ACC treatment.